DFTX
Definium Therapeutics, Inc.
November 2, 2026 · intraday
- Rarity
- 1.64
- Peak move
- −12.03%
- Float cap
- $3.4B
Still running — rarity and peak move can only rise from here.
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders in adults. Its lead candidates include DT120 ODT, a proprietary form of lysergide D-tartrate being developed for generalized anxiety disorder and major depressive disorder, and DT402, an R(-)-MDMA candidate for autism spectrum disorder.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.